Rolex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 07-12-2024
- Paid Up Capital ₹ 3.93 Cr
as on 07-12-2024
- Company Age 38 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
- Satisfied Charges ₹ 1.54 Cr
as on 07-12-2024
- Revenue -65.39%
(FY 2020)
- Profit -5.14%
(FY 2020)
- Ebitda -44.99%
(FY 2020)
- Net Worth 0.02%
(FY 2020)
- Total Assets -1.23%
(FY 2020)
About Rolex Pharmaceuticals
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 3.93 Cr.
The company has closed loans amounting to ₹1.54 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Amit Joshi, Ragini Joshi, and Dilipbhai Joshi serve as directors at the Company.
- CIN/LLPIN
U24232GJ1986PLC008767
- Company No.
008767
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
03 Jul 1986
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rolex Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dilipbhai Joshi  | Managing Director | 03-Jul-1986 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Amit Joshi | Director | 01-Jun-2010 | Current |
| Ragini Joshi | Director | 06-Jan-1992 | Current |
Financial Performance of Rolex Pharmaceuticals.
Rolex Pharmaceuticals Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 65.39% decrease. The company also saw a slight decrease in profitability, with a 5.14% decrease in profit. The company's net worth moved up by a moderate rise of 0.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rolex Pharmaceuticals?
In 2017, Rolex Pharmaceuticals had a promoter holding of 25.13% and a public holding of 74.87%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Industrial Development Bank Of India Creation Date: 31 Jan 1994 | ₹1.30 Cr | Satisfied |
Bank Of Baroda Creation Date: 08 Jul 1993 | ₹1.00 M | Satisfied |
Gujarat State Financial Corporation Creation Date: 27 Mar 1989 | ₹1.45 M | Satisfied |
How Many Employees Work at Rolex Pharmaceuticals?
Unlock and access historical data on people associated with Rolex Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rolex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rolex Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
